US 12,233,041 B2
Disulfonate stilbenes for use in the treatment of proliferative diseases
Fabrice Fleury, Orvault (FR); Alexandre Demeyer, Nantes (FR); Pierre Weigel, Orvault (FR); Benoit Chenais, Le Mans (FR); Monique Mathé, Nantes (FR); and Jacques Lebreton, Nantes (FR)
Assigned to UNIVERSITÉ DE NANTES, Nantes (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); and UNIVERSITÉ DU MANS, Le Mans (FR)
Appl. No. 17/295,231
Filed by UNIVERSITÉ DE NANTES, Nantes (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); and UNIVERSITÉ DU MANS, Le Mans (FR)
PCT Filed Nov. 22, 2019, PCT No. PCT/EP2019/082176
§ 371(c)(1), (2) Date May 19, 2021,
PCT Pub. No. WO2020/104634, PCT Pub. Date May 28, 2020.
Claims priority of application No. 18306546 (EP), filed on Nov. 22, 2018.
Prior Publication US 2022/0016068 A1, Jan. 20, 2022
Int. Cl. A61K 31/27 (2006.01); A61K 31/166 (2006.01); A61K 31/167 (2006.01); A61K 31/18 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/27 (2013.01) [A61K 31/166 (2013.01); A61K 31/167 (2013.01); A61K 31/18 (2013.01); A61K 45/06 (2013.01)] 11 Claims
OG exemplary drawing
 
1. A method of treatment of a cancer in a subject in need thereof, wherein the method comprises a step of administration to the subject of a compound of Formula (I)

OG Complex Work Unit Chemistry
wherein:
R0A and R0B are independently selected from the group consisting of hydrogen, lithium, sodium, and potassium; and
RA and RB are identical and selected from the group consisting of —NH—COOR, azido, cyano, and halide;
wherein each R is independently selected from the group consisting of (C1-C4)-alkyl and phenyl;
wherein the phenyl is optionally substituted by one or two substituent(s) independently selected from the group consisting of (C1-C3)-alkyl, (C1-C3)-alkoxy, and nitro;
or a pharmaceutically acceptable salt thereof.